- Home
- NMRK vs IRON Comparison
NMRK vs IRON Comparison
Compare NMRK & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMRK | IRON |
|---|---|---|
| Founded | 1929 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMRK | IRON |
|---|---|---|
| Price | $14.75 | $70.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $18.75 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 1.2M | 371.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $3,294,024,000.00 | N/A |
| Revenue This Year | $12.45 | N/A |
| Revenue Next Year | $8.02 | $283.52 |
| P/E Ratio | $191.50 | ★ N/A |
| Revenue Growth | ★ 20.29 | N/A |
| 52 Week Low | $11.12 | $40.00 |
| 52 Week High | $19.84 | $99.50 |
Technical Indicators
Market Signals| Indicator | NMRK | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 52.93 |
| Support Level | $13.67 | $64.48 |
| Resistance Level | $15.09 | $71.85 |
| Average True Range (ATR) | 0.55 | 3.32 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 54.42 | 59.40 |
Price Performance
Historical ComparisonAbout NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.